Lenka Sadilkova

Company: Mablink, a Wholly Owned Subsidary of Eli Lily & Company

Job title: Head of Preclinical Research and Development

Seminars:

Overviewing Payload Classes & Exploring Potency & Toxicity Concerns: What is the Next Frontier in ADC Payloads? 9:00 am

ADCs have demonstrated impressive clinical efficacy in several tumor types, however resistance and a competitive environment for some of these clinically validated payloads is driving drug developers to identify novel mechanisms of action and optimize payload structure with analogues of traditional payloads. With such a wide scope of development of ADC payloads following huge successes…Read more

day: Pre-Conference Workshop Day - Workshop A